Background: The incidence of cardiogenic shock (CS) in patients with ST-segment elevation myocardial infarction (STEMI) is as high as 10%. The majority of patients are thought to develop CS after admission (late CS), but the incidence in a contemporary STEMI cohort admitted for primary percutaneous intervention remains unknown. Aim: The aim of this study was to assess the incidence and time of CS onset in patients with suspected STEMI admitted in two high-volume tertiary heart centres and to assess the variables associated with the development of late CS. Methods: We included consecutive patients admitted for acute coronary angiography with suspected STEMI in a 1-year period. Cardiogenic shock was based on clinical criteria and subdivided into patients with shock on admission, patients developing shock during catheterisation and patients developing shock later during hospitalisation. Follow-up for allcause mortality was done using registries. Results: A total of 2247 patients with suspected STEMI were included, whereof 225 (10%) developed CS. The majority (56%) had CS on admission, 16% developed CS in the catheterisation laboratory and 28% developed late CS. Thirty-day mortality was 3.1% versus 47% in non-CS versus CS patients (p logrank < 0.0001). Age, stroke, time from symptom onset to intervention, anterior STEMI, heart rate/systolic blood pressure ratio and being comatose after resuscitation from cardiac arrest were independently associated with the development of late CS. Conclusion: In this study, 10% of patients admitted with suspected STEMI for acute coronary angiography presented with or developed CS. Most were in shock on admission. Irrespective of the timing of shock, mortality was high.
Introduction
During the past 30 years, all-cause mortality in patients with acute myocardial infarction (AMI) has been reduced dramatically. 1 Despite a potential overall reduction in incidence and mortality in patients presenting with ST-segment elevation myocardial elevation (STEMI) over the past decades, 1,2 patients presenting with STEMI complicated by cardiogenic shock (CS) have a short-term (in-hospital or 30-day) mortality approaching 50%. [1] [2] [3] [4] [5] [6] [7] [8] Data from both prior to and after the introduction of primary percutaneous coronary intervention (pPCI) have shown that only a minority of STEMI patients developing CS after admission show signs of shock on admission. [5] [6] [7] 9, 10 As prognosis in patients with CS is grave and evidence-based treatment is limited in patients with fulminant CS, the identification of patients in a pre-CS state may be important.
Contemporary data on the incidence and timing of CS onset in STEMI patients admitted for pPCI are limited, and accordingly, we sought to assess this. Furthermore, we aimed to investigate the relationship between demographic, electrocardiographic (ECG) and initial haemodynamic information and coronary anatomy and the development of CS. Thirdly, we aimed to assess associations between these variables and all-cause mortality in the overall cohort.
Materials and methods
The study was designed as a prospective, observational study including consecutive patients admitted for acute coronary angiography (CAG) due to suspected STEMI from two tertiary heart centres (Copenhagen University Hospital, Rigshospitalet [RH] , Denmark, and Odense University Hospital [OUH], Denmark). The two tertiary centres cover two-thirds of all patients in Denmark admitted for pPCI 11 and 3.8 million citizens in total. 12 In Denmark, all patients with symptoms and pre-hospital ECG changes suggestive of STEMI are referred for acute CAG and pPCI if revascularisation is indicated.
Study population
In total, 2713 consecutive patients were screened. A total of 1738 patients were screened at RH from 1 March 2015 to 28 February 2016 and 975 patients were screened at OUH from 1 October 2015 to 31 August 2016. All patients admitted for acute CAG were enrolled in the screening population regardless of suspected disease aetiology to avoid selection bias. From this population, we consecutively included patients admitted with suspicion of STEMI regardless of the clinical situation, thus including patients who were resuscitated from cardiac arrest.
Patients were excluded if they were younger than 18 years of age or refused to give written consent. In incapacitated patients unable to give informed consent, consent by proxy was obtained from the patient's next of kin and subsequently the patient's general practitioner in accordance with the Danish national legislation.
Patient onset of symptoms, demographics, initial haemodynamic status (first measured blood pressure and heart rate on admission), ECG (STEMI localisation, bundle branch block, arrhythmia, and atrioventricular block) and echocardiographic (left ventricular ejection fraction [LVEF] , valve disease, mechanical complication and right ventricular function) variables were registered. ECG variables were registered from the diagnostic ECG. Echocardiographic variables were registered from a bedside examination performed upon admission (n = 1487) and/or an echocardiography performed within 48 hours of admission (n = 1499). In 88 (3.9%) patients with suspected STEMI, LVEF was not available. Clinical biochemistry was available from the respective centres.
Shock index (SI) 4 was used as a marker of haemodynamic status combining heart rate and systolic blood pressure calculated as log1.1(heart rate divided by systolic blood pressure) that equals a 10% difference in SI level.
Pre-hospital treatment with antiplatelet therapy and heparin, coronary anatomy and revascularisation strategy were also registered. All data were entered into an electronic case report form.
Endpoints and definition of CS
The primary endpoint of the study was development of CS. Patients were considered to be in CS when fulfilling the following three criteria: a) A systolic blood pressure of <90 mmHg for more than 30 minutes or the need of a vasopressor/inotropic agent to maintain adequate blood pressure; b) Signs of end-organ hypoperfusion, defined as one or more of the following symptoms: cold and clammy extremities, oliguria and/or confusion or comatose state; c) Echocardiographic LVEF <45%.
The diagnosis of CS was done from prospectively obtained data as well as chart review (with repeatedly measured blood pressures) upon agreement between two sets of investigators (JE Møller, R Hansen and OK Møller-Helgestad at OUH and MG Lindholm and M Frydland at RH). In case of disagreement, a third investigator (C Hassager) assessed the patient. In all cases, consultant cardiologists were part of the adjudication.
CS patients were stratified according to the onset of CS into the following groups: CS on admission; CS developed in the catheterisation laboratory; and CS diagnosed after transfer to the ward (late CS). All-cause mortality was assessed using the Danish Civil Registration System, in which all Danish citizens are recorded with a unique 10-digit personal number and where all deaths in Denmark are registered within 2 weeks. Initial follow-up began on the date of admission. Follow-up of patients continued until date of death, or 30 October 2016. The secondary endpoint was all-cause 30-day mortality.
Statistics
Categorical variables are presented as number and percentages. Continuous variables are presented as means with SDs, or medians and 25th-75th percentiles for variables with a skewed distribution.
Comparisons between groups were performed using the χ 2 test, the Student's independent sample t-test or the Mann-Whitney U-test, as appropriate.
The predictive value of an early multimodal assessment on the development of CS after admission was shown as the C-value equal to the area under the receiver operating characteristics curve (AUC).
A logistic regression model including sex, age, smoking, hypertension, diabetes, previous stroke/transient ischaemic attack (TIA), peripheral artery disease, known kidney dysfunction (known creatinine level >100 μmol/L and/or dialysis), heart failure (LVEF <45%), anterior STEMI, three-vessel disease, left main (LM) culprit, log2(time from symptom debut to intervention), pre-PCI log1.1(SI), culprit artery post-PCI 'thrombolysis in myocardial infarction' (TIMI) flow as a class variable with TIMI grade 3 flow as reference and pre-admission cardiac arrest leading to a comatose state were used in order to identify variables associated with the development of late CS.
A Cox proportional hazard model including sex, age, smoking, hypertension, diabetes, previous stroke/TIA, peripheral artery disease, known kidney dysfunction, heart failure, anterior STEMI, three-vessel disease, LM culprit, log2(time from symptom debut to intervention), pre-PCI log1.1(SI), LVEF, culprit artery post-PCI TIMI flow as a class variable with TIMI grade 3 flow as reference, CS with different onset times as a class variable with no CS as reference and pre-admission cardiac arrest leading to a comatose state were used in order to assess 30-day mortality in the overall cohort.
Differences in mortality between groups were depicted with Kaplan-Meier curves and compared with the logrank test.
Multivariable models were constructed in order to identify independent associations for the outcomes by using backwards selection, with a significance level of 0.05 needed in order to stay in the model. Statistical analyses were performed using SAS Enterprise software version 7.4 (SAS Institute, Cary, NC, USA). A two-sided p-value < 0.05 was considered significant throughout.
Results
Of the 2713 patients admitted for acute CAG, 2247 (83%) patients were eligible for inclusion as patients admitted for pPCI with a suspicion of STEMI on the ECG. Of these, 1791 (80%) patients had pPCI performed, 205 (9.1%) had staged PCI performed and 77 (3.4%) had surgery with coronary artery bypass grafting (CABG) performed.
A total of 225 (10%) patients developed CS. Of these, 126 (56%) patients presented with CS on admission, 35 (16%) patients developed CS in the catheterisation laboratory and 64 (28%) patients developed late CS ( Figure 1 ). Time from admission to late CS onset was a median of 12.5 hours (25th-75th percentile: 4.0-30.5 hours). Mortality in CS patients and in the overall cohort was similar between the two centres.
Patients with late CS were older and had more cardiovascular comorbidities, including heart failure and ischaemic heart disease compared to patients without CS (Table  1 ). Late CS patients had an overall longer time from onset of symptoms to CAG, irrespective of patients who were comatose after cardiac arrest being excluded. When comatose cardiac arrest patients were excluded, patients with late CS had longer times from ECG recording to intervention. In late CS patients, anterior STEMI was more often present in the pre-hospital ECG compared to patients without CS, whereas inferior/posterior STEMI was more often present in the latter group (p = 0.007 for trend). Despite Table 1 . Baseline data. Baseline characteristics of patients with suspected ST-segment elevation myocardial infarction without cardiogenic shock and patients with cardiogenic shock.
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Bold 22 , p = 0.001), a higher SI (OR for 10% higher level 1.28, 95% CI 1.13-1.44), p < 0.0001) and being comatose after resuscitation from cardiac arrest (OR 17.04, 95% CI 5.14-56.67, p < 0.0001) were independently associated with development of late CS ( Table 2 ). The overall predictive value for the model with regards to the development of late CS was good (AUC = 0.868). When excluding patients who were comatose after cardiac arrest, the abovementioned variables remained independently associated with development of late CS. The predictive value of the model remained good (AUC = 0.865).
All-cause 30-day mortality in patients with CS was 47% compared to 3.1% in patients without CS (p logrank < 0.0001; Figure 2 ). When stratifying CS patients on timing of onset In a Cox proportional hazard model, age, LVEF, peripheral artery disease, being comatose after resuscitation from cardiac arrest, increasing time from onset of symptoms to intervention and CS (irrespective of onset time) were independently associated with 30-day mortality in the overall cohort (Table 3) . When excluding comatose cardiac arrest patients, age, peripheral artery disease, LVEF and time from onset of symptoms to intervention, CS remained independently associated with 30-day mortality (data not shown).
Discussion
In this study, we found that 1 in 10 patients admitted to acute CAG for suspected STEMI develops CS. In 28% of the CS patients in our study, shock onset occurred after leaving the catheterisation laboratory. Late CS patients were older, had a greater comorbidity burden, had more severe coronary disease and had more unfavourable haemodynamic status and LVEF on admission compared to patients without CS.
More than half of the CS patients presented with shock on admission, which is in contrast to previous studies stating that most CS patients are stable on admission and develop shock later. 5-7,9,10 A possible explanation for this is a higher rate of patients resuscitated from cardiac arrest (46%) being haemodynamically unstable on admission to the PCI centre compared to previous studies. 6, 9, 10, 13 In addition, early revascularisation due to improved infrastructure and revascularisation strategies may cause fewer patients to have great left ventricular myocardial loss when compared to data from the pre-PCI era, and therefore fewer patients developing late CS. 5 In accordance with previous studies, we found that STEMI patients with complicating CS were older, had greater comorbidity 6, 7, [14] [15] [16] [17] and had a greater burden of atherosclerotic coronary disease with a higher frequency of multivessel disease and LM as the culprit lesion 7, 16 compared to patients without CS. Furthermore, patients with CS onset before admission were younger than patients with late CS. 6 Patients with late CS had increased patient and system delays (time from symptom onset and ECG recording to intervention), which have been previously associated with reduced survival in STEMI patients. 8, 18, 19 Besides traditional variables (age and severe cardiovascular disease affecting the left ventricle), SI assessed directly on admission was a significant risk factor of late development of CS. SI illustrates a simple evaluation of a patient's haemodynamic status, combining heart rate and systolic blood pressure. SI has previously been shown to be associated with short-term outcomes in STEMI patients. 4, 20, 21 To our knowledge, this is the first study to demonstrate a strong association between SI assessed immediately after admission and the development of late CS.
Comatose cardiac arrest patients were at risk of developing late CS. Patients being comatose after cardiac resuscitation are often haemodynamically fragile, and a third of post-resuscitation mortalities are caused by cardiovascular instability. 22 The pathophysiology may be different from the late CS that developed in patients without cardiac arrest, although this is speculative.
A mortality rate of approximately 50% in patients with CS is in accordance with previous findings. [1] [2] [3] [4] [5] [6] [7] [8] 13, [23] [24] [25] [26] [27] This was independent of CS onset time.
Despite substantial improvements in the treatment of STEMI that have occurred over the last decades, the prognosis for patients who deteriorate into CS remains poor. [1] [2] [3] Data from studies of both the pre-and post-pPCI eras suggest that a large proportion of STEMI patients who deteriorate into CS are stable upon admission to the hospital. [5] [6] [7] 9 Time from admission to CS development may prove to be a vital time window of diagnosis and intervention before the shock progresses to irreversible organ failure. 28 Previous interventional studies on CS patients have all shown discouraging results in terms of short-term outcomes. 13, [24] [25] [26] [27] Only early revascularisation has led to a decrease in 1-year mortality when compared to initial medical stabilisation in the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial almost 20 years ago. 23 Therefore, the identification of patients at a high risk of CS development is of great interest. Increased surveillance, intensive care and potential interventions with, for example, re-CAG/PCI and mechanical support in patients in a pre-shock state could potentially prevent the development of fulminant CS. Studies in this group of patients may be considered for future research. Data from this study suggest that clinicians should pay great attention to elderly patients with long time from symptom debut to intervention, severe cardiovascular disease affecting the left ventricle, moderate hypotension, and an increased heart rate. Early LVEF assessment should probably be performed in these patients for risk stratification. A simple, early biomarker of late CS development would certainly aid clinicians in identifying patients who are at risk and in prioritising resources for intensified care in this subgroup.
Limitations
We were unable to obtain consent for study participation in 93 (3.4%) patients, leading to a potential selection bias. However, no patients in this group died during admission. In 88 (3.9%) of the included patients, LVEF was not assessed, potentially over-or under-estimating the importance of LVEF. A concern would be the generalisability of this study, as virtually all STEMI patients in Denmark are treated with pPCI <120 minutes after field triage. 29 The applicability of the findings in this study may thus be reduced for countries with high rates of STEMI patients treated with thrombolysis and in countries with substantially longer times from symptom debut to pPCI. 30 
Conclusion
CS remains a frequent complication in patients who are suspected of STEMI. Early risk prediction allowing for appropriate monitoring and interventions may reduce mortality, which is still at approximately 50%. While early clinical predictions from clinical variables are good, perhaps combining these with biochemical risk markers may prove useful for improving the early identification of highrisk patients. 
